1st patient dosed in Phase 2 trial of Parkinson’s therapy VTX3232

Ventyx Biosciences has begun dosing the first patient in a Phase 2a trial of VTX3232, an oral drug targeting early-stage Parkinson’s disease. The trial, taking place in New Haven, Connecticut, aims to assess the safety and tolerability of VTX3232 in about 10 participants. The drug works by inhibiting the NLRP3 protein to reduce brain inflammation, which is believed to play a role in Parkinson’s progression. Over the course of 28 days, patients will receive the drug, with a follow-up period of 14 days. The trial will also study how the drug moves through the body, its effects, and its potential to alter disease biomarkers. PET imaging will be used to examine brain immune cell activity related to inflammation. Previous Phase 1 trials showed that VTX3232 was well tolerated and effective in reducing key inflammatory markers, with no serious side effects reported. VTX3232 is also being considered for other neurodegenerative conditions like Alzheimer’s and multiple sclerosis. Top-line data from this study are expected in 2025.